Project Grant R41CA233111

Federal Project Grant Award Summary Glytr Therapeutics, Inc. received a $463,510 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 10, 2025, with a project completion date of August 31, 2028. The company is developing novel glycan-dependent T cell recruiter (GLYTR) pan-cancer immunotherapeutics designed to enhance cancer treatment by targeting tumor-associated carbohydrate antigens (TACAs). The research...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...

Federal Project Grant Award Summary Immunogenik, Inc. received a $398,997 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, with a completion date of June 30, 2026. The grant supports research and development of a novel immunotherapeutic approach targeting tumor-associated myeloid cells (TAMCs), including tumor-associated macrophages and myeloid-derived suppressor cells, which constitute up to 50% of certain...

Federal Grant Award Summary Ioncologi Inc. received a $276,544 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2026. The award funds the development of IOI7, an autologous stem cell biotherapeutic designed to overcome immune checkpoint inhibitor (ICI) resistance in glioblastoma patients. The project delivers two primary products: (1) optimization and validation of a closed-circuit, scalable...

Federal Grant Award Summary Glycyx Mor, Inc. received a $1.197 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 19, 2025, to conduct a Phase 2 clinical trial evaluating axelopran as an adjunctive therapy to pembrolizumab for treating recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in patients with PD-L1 CPS >1. The primary deliverable is clinical trial data demonstrating whether...

Federal Grant Award Summary Immunogenik, Inc. received a $398,997 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on June 9, 2025, with completion expected by May 31, 2026. The company is developing a clinical-grade humanized antibody (hu-ALAIR1) targeting Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR1/CD305) to overcome tumor-associated macrophage (TAM)-mediated immunosuppression in the tumor microenvironment. The...

This $641,936 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a novel approach using engineered chimeric antigen receptor (CAR)-neutrophils to treat glioblastoma, the most aggressive type of brain cancer. The principal investigators at Purdue University will harness synthetic biology, machine learning, and in vivo models to investigate programming tumor-associated neutrophils as anti-tumor effector cells. The proposed strategy...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

This federal Project Grant award of $270,981 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a five-year research program to investigate resistance mechanisms to anti-PD-1/L1 immunotherapy in hepatobiliary cancers. The key objectives are to: Conduct a Phase 2 trial evaluating an anti-TIGIT plus anti-PD-1 antibody combination in hepatobiliary cancers refractory to PD-1 blockade. Characterize immune and molecular features of anti-PD-1/L1 therapy-resistant...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,985 to Colorado State University to develop a novel liposomal-TLR agonist immunotherapy (LTAC) for the treatment of ocular surface squamous neoplasia (OSSN), a progressive form of ocular cancer. The key objectives are to: 1) Investigate the local immune responses induced by LTAC immunotherapy in an equine OSSN model, using tumor biopsies and corneal swabs to identify immune...